Scientific and clinical progress together with the development of effective novel therapeutic
options has engendered multiple important changes in the diagnosis and management of …

Background For the prevention of attacks of hereditary angioedema (HAE), the efficacy and
safety of subcutaneous human C1-esterase inhibitor (C1-INH [SC]; HAEGARDA, CSL …

The recent outbreak of the 2019 novel coronavirus disease (COVID-19) has been proved as
a global threat. No particular drug or vaccine has not yet been discovered which may act …

Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Patients with hereditary angioedema (HAE) experience a high burden of disease due to
unpredictable, painful, disfiguring, and potentially life‐threatening HAE attacks. Multiple HAE …

Background Hereditary angioedema (HAE) is a potentially life‐threatening inherited disease
that causes recurrent, serious, and debilitating episodes of swelling. While evidence has …

Background Hereditary angioedema (HAE) is a debilitating disorder resulting from C1-
esterase inhibitor (C1-INH) deficiency. In the COMPACT phase 3 study the prophylactic use …

Hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency is a rare disease
characterized by recurrent swellings. This study aims to determine (i) the clinical …

Background: There is limited real-world evidence on hereditary angioedema (HAE) patient
characteristics and health-care resource utilization (HCRU); in addition, pediatric patients …

Objectives: Describe the different types of hereditary angioedema. Outline the clinical
presentation of a patient with hereditary angioedema. Review the treatment considerations …